Patient-Reported Visual Function Outcomes After Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: Preplanned Secondary Analysis of a Randomized Clinical Trial

IMPORTANCE: Anti–vascular endothelial growth factor (anti-VEGF) therapy is the standard-of-care first-line treatment for macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO), and information is needed to assess the effect of anti-VEGF therapy on pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Ophthalmol
Main Authors: Scott, Ingrid U., VanVeldhuisen, Paul C., Barton, Franca, Oden, Neal L., Ip, Michael S., Blodi, Barbara A., Worrall, Martin, Fish, Gary E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555474/
https://ncbi.nlm.nih.gov/pubmed/31169862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2019.1519
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados